Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

Keynote webinar | Spotlight on medication adherence

LIVE: Thursday 27th June 2024, 18:00-19:30 (CEST)
Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.
ADVANCED SEARCH
Log in
Top
Current Diabetes Reports
Published in: Current Diabetes Reports 11/2015

01-11-2015 | Macrovascular Complications in Diabetes (VR Aroda and A Getaneh, Section Editors)

Sex-Specific Differential in Risk of Diabetes-Related Macrovascular Outcomes

Authors: Amanda Lyon, Elizabeth A. Jackson, Rita R. Kalyani, Dhananjay Vaidya, Catherine Kim

Published in: Current Diabetes Reports | Issue 11/2015

Login to get access

Abstract

Reports from recent studies suggest that diabetes confers a higher risk of cardiovascular disease in women compared to men. Larger studies, including meta-analyses, report that women with diabetes have a 44 % greater risk of incident coronary heart disease and a 27 % greater risk of incident stroke compared to men with diabetes. In this article, we summarize results from longitudinal studies that examine sex differences in risk factors for and rates of macrovascular complications from diabetes. We also discuss possible mechanisms for increased cardiovascular risk associated with diabetes in women compared to men, including the clustering of hypertension, obesity, and elevated triglycerides, the possible contribution of hormonal differences, and sex differences in the prescription of and adherence to pharmacologic treatment. In conclusion, diabetes is associated with a slightly higher risk of cardiovascular disease in women compared to men. Future studies should further explore the reasons underlying imperfect use of medications that lower cardiovascular risk in both women and men with diabetes.
Literature
1.
Kannel WB, McGee DL. Diabetes and cardiovascular disease. The Framingham study. JAMA. 1979;241:2035–8.CrossRefPubMed
2.••
Peters S, Huxley R, Woodward M. Diabetes as a risk factor for incident coronary heart disease in women compared with men: a systematic review and meta-analysis of 64 cohorts including 858,507 individuals and 28,203 coronary events. Diabetologia. 2014;57:1542–51. Meta-analysis that investigated prospective relationships between diabetes and incident CHD in men and women, reporting that women with diabetes have more than a 40% greater risk for developing CHD than men with diabetes.CrossRefPubMed
3.••
Peters S, Huxley R, Woodward M. Diabetes as a risk factor for stroke in women compared with men: a systematic review and meta-analysis of 64 cohorts, including 775 385 individuals and 12 539 strokes. Lancet. 2014;383:1973–80. Meta-analysis that investigated prospective relationships between diabetes and incident stroke in men and women, reporting that women with diabetes have a significantly higher risk of incident stroke than men with diabetes. They report these findings independent of sex differences in other major cardiovascular risk factors.CrossRefPubMed
4.
Huxley R, Hirakawa Y, Hussain M, Aekplakorn W, Wang X, Peters S, et al. Age- and sex-specific burden of cardiovascular disease attributable to 5 major and modifiable risk factors in 10 Asian countries of the Western Pacific Region. Circ J. 2015;79:1662–74.CrossRefPubMed
5.
Wildman RP, McGinn AP, Kim M, Muntner P, Wang D, Cohen HW, et al. Empirical derivation to improve the definition of the metabolic syndrome in the evaluation of cardiovascular disease risk. Diabetes Care. 2011;34:746–8.PubMedCentralCrossRefPubMed
6.
Gabir MM, Hanson RL, Dabelea D, Imperatore G, Roumain J, Bennett PH, et al. The 1997 American Diabetes Association and 1999 World Health Organization criteria for hyperglycemia in the diagnosis and prediction of diabetes. Diabetes Care. 2000;23:1108–12.CrossRefPubMed
7.
Expert Panel on Detection E. Treatment of high blood cholesterol in adults: executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (adult treatment panel III). JAMA. 2001;285:2486–97.CrossRef
8.
World Health Organization. Definition, diagnosis, and classification of diabetes mellitus and its complications: a report of WHO consultation. Part 1. Diagnosis and classification of diabetes mellitus Geneva, World Health Organization, 1999.
9.
Alberti KG, Zimmet P, Shaw J. Group IDFETFC: the metabolic syndrome—a new worldwide definition. Lancet. 2005;366:1059–62.CrossRefPubMed
10.
Wong ND. Epidemiological studies of CHD and the evolution of preventive cardiology. Nat Rev Cardiol. 2014;11:276–89.CrossRefPubMed
11.
The World Health Organization MONICA Project (monitoring trends and determinants in cardiovascular disease). A major international collaboration. WHO MONICA Project Principal Investigators. J Clin Epidemiol. 1988;41:105–14.CrossRef
12.
You R, McNeil JJ, O'Malley HM, Davis SM, Donnan GA. Risk factors for lacunar infarction syndromes. Neurology. 1995;45:1483–7.CrossRefPubMed
13.
Tuttolomondo A, Pinto A, Salemi G, Di Raimondo D, Di Sciacca R, Fernandez P, et al. Diabetic and non-diabetic subjects with ischemic stroke: differences, subtype distribution and outcome. Nutr Metab Cardiovasc Dis. 2008;18:152–7.CrossRefPubMed
14.
Easton J, Saver J, Albers G, Alberts M, Chaturvedi S, Feldmann E, et al. Definition and evaluation of transient ischemic attack: a scientific statement for healthcare professionals from the AHA/ASA stroke council. Stroke. 2009;40:2276–93.CrossRefPubMed
15.••
Kalyani R, Lazo M, Ouyang P, Turkbey E, Chevalier K, Brancati F, et al. Sex differences in diabetes and risk of incident coronary artery disease in healthy young and middle-aged adults. Diabetes Care. 2014;37:830–8. Report that investigated sex differential among young and middle-aged adults without coronary disease. The presence of a sex differential even among younger adults suggests that aggressive therapy in this population with statins and anti-platelet agents may be beneficial.PubMedCentralCrossRefPubMed
16.
Peters S, Huxley R, SAttar N, Woodward M. Sex differences in the excess risk of cardiovascular diseases associated with type 2 diabetes: potential explanations and clinical implications. Curr Cardiovasc Risk Rep. 2015;9:36.PubMedCentralCrossRefPubMed
17.
The Atherosclerosis Risk in Communities (ARIC) Study. Design and objectives. The ARIC investigators. Am J Epidemiol. 1989;129:687–702.
18.
Colditz GA, Martin P, Stampfer MJ, Willett WC, Sampson L, Rosner B, et al. Validation of questionnaire information on risk factors and disease outcomes in a prospective cohort study of women. Am J Epidemiol. 1986;123:894–900.PubMed
19.
Baviera M, Santalucia P, Coretesi L, Morzona I, Tettamanti M, Avanzini F, et al. Sex differences in cardiovascular outcomes, pharmacologic treatments and indicators of care in patients with newly diagnosed diabetes: Analyses on administrative database. Eur J Intern Med. 2014;25:270–5.CrossRefPubMed
20.
Guzder R, Gatling W, Mullee M, Byrne C. Early mortality from the time of diagnosis of Type 2 diabetes: a 5-year prospective cohort study with a local age- and sex-matched comparison cohort. Diabet Med. 2007;24:1164–7.CrossRefPubMed
21.
Hadaegh F, Fahimfar N, Khalili D, Sheikholeslami F, Azizi F. New and known type 2 diabetes as coronary heart disease equivalent: results from 7.6 year follow up in a Middle East population. Cardiovasc Diabetol. 2010.
22.
Kim H, Kim C, Kim E, Bae S, Chloe J, Park J, et al. Impaired fasting glucose and risk of cardiovascular disease in Korean men and women: the Korean heart study. Diabetes Care. 2013;36:328–35.PubMedCentralCrossRefPubMed
23.
Mak K, Ma S, Heng D, Tan C, Tai E, Topol E, et al. Impact of sex, metabolic syndrome, and diabetes mellitus on cardiovascular events. Am J Cardiol. 2007;100:227–33.CrossRefPubMed
24.
Schottker B, Muller H, Rothenbacher D, Brenner H. Fasting plasma glucose and HbA1c in cardiovascular risk prediction: a sex-specific comparison in individuals without diabetes mellitus. Diabetologia. 2013;56:92–100.CrossRefPubMed
25.
Zhao W, Katzmarzyk P, Horswell R, Wang Y, Johnson J, Hu G. Sex differences in the risk of stroke and HbA1c among diabetic patients. Diabetologia. 2014;57:918–26.PubMedCentralCrossRefPubMed
26.
Yamagishi K, Ikeda A, Iso H, Inoue M, Tsugane S, Group JS. Self-reported stroke and myocardial infarction had adequate sensitivity in a population-based prospective study JPHC (Japan Public Health Center)-based prospective study. J Clin Epidemiol. 2009;62:667–73.CrossRefPubMed
27.
Criqui M, Barrett-Connor E, Holdbrook M, Austin M, Turner J. Clustering of cardiovascular disease risk factors. Prev Med. 1980;9:525–33.CrossRefPubMed
28.
Wingard D, Suarez L, Barrett-Connor E. The sex differential in mortality from all causes and ischemic heart disease. Am J Epidemiol. 1983;117:165–72.PubMed
29.
Kanaya A, Grady D, Barrett-Connor E. Explaining the sex difference in coronary heart disease mortality among patients with type 2 diabetes mellitus: a meta-analysis. Arch Intern Med. 2002;162:1737–45.CrossRefPubMed
30.••
Regensteiner J, Golden S, Barrett-Connor E, Chang A, Chyun D, Fox C et al. Sex differences in the cardiovascular consequences of diabetes mellitus: american Heart association scientific statement. Circulation. 2015. This extensive review of the management of diabetes and CVD risk factors in women specifically includes a review of pregnancy-related complications and pharmacologic therapies, as well as other women-specific risk factors such as polycystic ovarian syndrome
31.
Kim C, Cushman M, Kleindorfer D, Safford M, Redberg R, Lisabeth L. A review of the relationships between endogenous sex steroids and incident ischemic stroke and coronary heart disease events. Curr Cardiol Rev. 2015.
32.
33.
Barrett-Connor E, Cohn B, Wingard D, Edelstein S. Why is diabetes mellitus a stronger risk factor for fatal ischemic heart disease in women than in men? The Rancho Bernardo Study. JAMA. 1991;265:627–31.CrossRefPubMed
34.
Ding E, Song Y, Malik V, Liu S. Sex differences of endogenous sex hormones and risk of type 2 diabetes. JAMA. 2006;295:1288–99.CrossRefPubMed
35.
Corona G, Monami M, Rastrelli G, Aversa A, Sforza A, Lenzi A, et al. Type 2 diabetes mellitus and testosterone: a meta-analysis study. Int J Androl. 2010;34:528–40.CrossRefPubMed
36.
Barrett-Connor E. Why women have less heart disease than men and how diabetes modifies women's usual cardioprotection. Glob Heart. 2013;8:95–104.CrossRef
37.
Kalyani RR, Franco M, Dobs AS, Ouyang P, Vaidya D, Bertoni A, et al. The association of endogenous sex hormones, adiposity, and insulin resistance with incident diabetes in postmenopausal women. J Clin Endocrinol Metab. 2009;94:4127–35.PubMedCentralCrossRefPubMed
38.
Kim C, Halter J. Endogenous sex hormones, metabolic syndrome, and diabetes in men and women. Curr Cardiol Rep. 2014; 16.
39.
Regensteiner J, Bauer T, Huebschmann A, Herlache L, Weinberger H, Wolfel E, et al. Sex differences in the effects of type 2 diabetes on exercise performance. Med Sci Sports Exerc. 2015;47:58–65.CrossRefPubMed
40.
Kerr A, Exeter D, Hanham G, Grey C, Zhao J, Riddell T, et al. Effect of age, gender, ethnicity, socioeconomic status and region on dispensing of CVD secondary prevention medication in New Zealand: the Atlas of Health Care Variation CVD cohort (VIEW-1). N Z Med J. 2014;127:39–69.PubMed
41.
Vimalananda V, Miller D, Hofer T, Holleman R, Klamerus M, Kerr E. Accounting for clinical action reduces estimates of gender disparities in lipid management for diabetic veterans. J Gen Intern Med. 2013;28 Suppl 2:S529–535.CrossRefPubMed
42.
Huxley R, Barzi F, Woodward M. Excess risk of fatal coronary heart disease associated with diabetes in men and women: meta-analysis of 37 prospective cohort studies. BMJ. 2006;332:73–8.PubMedCentralCrossRefPubMed
43.
Billimek J, Malik S, Sorkin D, Schmalbach P, Ngo-Metzger Q, Greenfield S, et al. Understanding disparities in lipid management among patients with type 2 diabetes: gender differences in medication nonadherence after treatment intensification. Womens Health Issues. 2015;25:6–12.CrossRefPubMed
44.
Trialists CT, Baigent C, Blackwell L, Emberson J, Holland L, Reith C et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010; 376.
45.
Stone NJ, Robinson JG, Lichtenstein AH, Bairey Merz CN, Blum CB, Eckel RH, et al. American College of Cardiology/American Heart Association Task Force on practice G: 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines. Circulation. 2014;129:S1–45.CrossRefPubMed
46.
Cull CA, Neil HA, Holman RR. Changing aspirin use in patients with type 2 diabetes in the UKPDS. Diabet Med. 2004;21:1368–71.CrossRefPubMed
47.
Antithrombotic Trialists C, Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data form randomised trials. Lancet. 2009;373:1849–60.CrossRef
48.
De Berardis G, Sacco M, Strippoli GF, Pellegrini F, Graziano G, Tognoni G, et al. Aspirin for primary prevention of cardiovascular events in people with diabetes: meta-analysis of randomised controlled trials. BMJ. 2009;339:b4531.PubMedCentralCrossRefPubMed
49.
Metti A, Yaffe K, Boudreau R, Ganguli M, Lopez O, Stone K, et al. Change in inflammatory markers and cognitive status in the oldest-old women from the study of osteoporotic fractures. J Am Geriatr Soc. 2014;62:662–6.PubMedCentralCrossRefPubMed
50.
Stratton IM, Adler AI, Neil HA, Matthews DR, Manley SE, Cull CA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ. 2000;321:405–12.PubMedCentralCrossRefPubMed
51.
Selvin E, Marinopoulos S, Berkenblit G. Meta-analysis: glycosylated hemoglobin and cardiovascular disease in diabetes mellitus. Ann Intern Med. 2004;141:421–31.CrossRefPubMed
52.
Reichard P, Bengt-Nilsson B, Rosenqvist U. The effect of long-term intensified insulin treatment on the development of microvascular complications of diabetes mellitus. N Engl J Med. 1993;329:304–9.CrossRefPubMed
53.
Action to Control Cardiovascular Risk in Diabetes Study G, Gerstein HC, Miller ME, Byington RP, Goff Jr DC, Bigger JT, et al. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358:2545–59.CrossRef
54.
The ADVANCE Collaborative Group. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358:2560–72.CrossRef
55.
UK Prospective Diabetes Study Group. Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes. BMJ. 1998;317:703–13.PubMedCentralCrossRef
56.
Larkin M, Backlund J, Cleary P, Bayless M, Schaefer B, Canady J, et al. DCCT/EDIC Group: Disparity in management of diabetes and coronary heart disease risk factors by sex in DCCT/EDIC. Diabet Med. 2010;27:451–8.CrossRefPubMed
Metadata
Title
Sex-Specific Differential in Risk of Diabetes-Related Macrovascular Outcomes
Authors
Amanda Lyon
Elizabeth A. Jackson
Rita R. Kalyani
Dhananjay Vaidya
Catherine Kim
Publication date
01-11-2015
Publisher
Springer US
Published in
Current Diabetes Reports / Issue 11/2015
Print ISSN: 1534-4827
Electronic ISSN: 1539-0829
DOI
https://doi.org/10.1007/s11892-015-0662-x

Other articles of this Issue 11/2015

Current Diabetes Reports 11/2015 Go to the issue

Microvascular Complications—Retinopathy (JK Sun, Section Editor)

Sustained-Release Steroids for the Treatment of Diabetic Macular Edema

Treatment of Type 1 Diabetes (M Pietropaolo, Section Editor)

The Detection and Management of Diabetes Distress in People With Type 1 Diabetes

Pathogenesis of Type 1 Diabetes (A Pugliese, Section Editor)

T Cell Epitopes and Post-Translationally Modified Epitopes in Type 1 Diabetes

Microvascular Complications—Neuropathy (R Pop-Busui, Section Editor)

Is There a Relationship Between Oral Health and Diabetic Neuropathy?

Health Care Delivery Systems and Implementation in Diabetes (EB Morton-Eggleston, Section Editor)

Strategies for Improving Cardiovascular Health in Women With Diabetes Mellitus: a Review of the Evidence

Genetics (AP Morris, Section Editor)

Progress in Understanding Type 1 Diabetes Through Its Genetic Overlap with Other Autoimmune Diseases
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine
Obesity Clinical Trial Summary

At a glance: The STEP trials

Read more

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits